Supernus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SUPN)

$39.50 0.45 (1.15 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$39.05
Today's Range$38.80 - $39.75
52-Week Range$20.55 - $50.04
Volume117,822 shs
Average Volume613,826 shs
Market Capitalization$2.00 billion
P/E Ratio36.84
Dividend YieldN/A
Beta1.3

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500

Debt

Debt-to-Equity RatioN/A
Current Ratio1.82%
Quick Ratio1.68%

Price-To-Earnings

Trailing P/E Ratio36.84
Forward P/E Ratio36.92
P/E Growth1.65

Sales & Book Value

Annual Sales$215 million
Price / Sales9.42
Cash Flow$1.08 per share
Price / Cash36.74
Book Value$4.91 per share
Price / Book8.04

Profitability

Trailing EPS$1.06
Net Income$91.22 million
Net Margins20.98%
Return on Equity26.37%
Return on Assets17.00%

Miscellaneous

Employees363
Outstanding Shares51,260,000

Frequently Asked Questions for Supernus Pharmaceuticals (NASDAQ:SUPN)

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) announced its earnings results on Monday, November, 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.27 by $0.02. The specialty pharmaceutical company earned $80.40 million during the quarter, compared to analysts' expectations of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The business's revenue was up 41.5% compared to the same quarter last year. View Supernus Pharmaceuticals' Earnings History.

Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?

9 Wall Street analysts have issued 1 year price targets for Supernus Pharmaceuticals' stock. Their predictions range from $41.00 to $61.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $49.89 in the next twelve months. View Analyst Ratings for Supernus Pharmaceuticals.

What are Wall Street analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (11/10/2017)
  • 2. FBR & Co analysts commented, "We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions." (10/19/2017)
  • 3. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
  • 4. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)

Who are some of Supernus Pharmaceuticals' key competitors?

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:

  • Charles W. Newhall III, Independent Chairman of the Board (Age 72)
  • Jack A. Khattar, President, Chief Executive Officer, Secretary, Director (Age 55)
  • Gregory S. Patrick, Chief Financial Officer, Vice President (Age 65)
  • Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer (Age 65)
  • Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer (Age 59)
  • Victor Vaughn, Senior Vice President - Sales and Marketing (Age 59)
  • Georges Gemayel Ph.D., Independent Director (Age 56)
  • Frederick M. Hudson CPA, Independent Director (Age 71)
  • William A. Nuerge, Independent Director (Age 64)
  • John M. Siebert Ph.D., Independent Director (Age 77)

Who owns Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (2.93%), Rice Hall James & Associates LLC (2.41%), Rothschild Asset Management Inc. (2.22%), Russell Investments Group Ltd. (1.65%), Ashford Capital Management Inc. (1.47%) and Neumeier Poma Investment Counsel LLC (1.41%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, M James Barrett, Padmanabh P Bhatt and Stefan KF Schwabe. View Institutional Ownership Trends for Supernus Pharmaceuticals.

Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bruce & Co. Inc., Russell Investments Group Ltd., Allianz Asset Management GmbH, Neumeier Poma Investment Counsel LLC, Rice Hall James & Associates LLC, Granite Investment Partners LLC, American Century Companies Inc. and Macquarie Group Ltd.. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Padmanabh P Bhatt and Stefan KF Schwabe. View Insider Buying and Selling for Supernus Pharmaceuticals.

Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Scout Investments Inc., Janus Henderson Group PLC, Oak Ridge Investments LLC, Nationwide Fund Advisors, Mesirow Financial Investment Management Equity Management, Emerald Advisers Inc. PA and Ameriprise Financial Inc.. View Insider Buying and Selling for Supernus Pharmaceuticals.

How do I buy Supernus Pharmaceuticals stock?

Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $39.50.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $2.00 billion and generates $215 million in revenue each year. The specialty pharmaceutical company earns $91.22 million in net income (profit) each year or $1.06 on an earnings per share basis. Supernus Pharmaceuticals employs 363 workers across the globe.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]


MarketBeat Community Rating for Supernus Pharmaceuticals (SUPN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Supernus Pharmaceuticals (NASDAQ:SUPN)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.502.602.71
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $47.27$45.67$45.38$29.83
Price Target Upside: 24.08% upside10.31% upside0.60% downside10.68% downside

Consensus Price Target History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Price Target History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017B. RileyReiterated RatingBuy$50.00N/AView Rating Details
11/7/2017Stifel NicolausUpgradeHold -> Buy$47.00N/AView Rating Details
11/3/2017SunTrust Banks, Inc.Reiterated RatingBuy$61.00N/AView Rating Details
10/29/2017Piper Jaffray CompaniesSet Price TargetHold$41.00N/AView Rating Details
10/23/2017Cowen IncSet Price TargetBuy$50.00N/AView Rating Details
10/19/2017FBR & CoInitiated CoverageBuy -> Buy$53.00N/AView Rating Details
9/27/2017Cantor FitzgeraldReiterated RatingBuy$49.00LowView Rating Details
9/20/2017Jefferies Group LLCReiterated RatingBuy$51.00HighView Rating Details
9/20/2017Janney Montgomery ScottReiterated RatingHold$47.00LowView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Supernus Pharmaceuticals (NASDAQ:SUPN)

Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Earnings History by Quarter for Supernus Pharmaceuticals (NASDAQ SUPN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017$0.27$0.29$78.74 million$80.40 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.24$0.32$68.54 million$75.83 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.22$0.19$57.91 million$57.58 millionViewListenView Earnings Details
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
2017 EPS Consensus Estimate: $0.97
2018 EPS Consensus Estimate: $1.63
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.16$0.24$0.20
Q2 20172$0.23$0.25$0.24
Q3 20174$0.27$0.30$0.28
Q4 20174$0.19$0.29$0.25
Q1 20182$0.18$0.27$0.23
Q2 20182$0.39$0.42$0.41
Q3 20182$0.48$0.48$0.48
Q4 20182$0.50$0.53$0.52
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Supernus Pharmaceuticals (NASDAQ SUPN)

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 94.70%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ SUPN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2017Gregory S. PatrickCFOSell50,000$47.60$2,380,000.00View SEC Filing  
9/8/2017Padmanabh P BhattSVPSell5,000$49.86$249,300.00View SEC Filing  
9/7/2017Stefan K.F. SchwabeInsiderSell95,000$46.59$4,426,050.00View SEC Filing  
8/16/2017Padmanabh P BhattVPSell3,709$45.23$167,758.07View SEC Filing  
7/12/2017Padmanabh P BhattVPSell3,735$44.90$167,701.50View SEC Filing  
6/23/2017Padmanabh P BhattVPSell2,556$44.90$114,764.40View SEC Filing  
6/2/2017Padmanabh P BhattVPSell10,000$39.86$398,600.00View SEC Filing  
5/26/2017Padmanabh P BhattVPSell2,500$35.90$89,750.00View SEC Filing  
5/25/2017Padmanabh P BhattVPSell5,500$34.90$191,950.00View SEC Filing  
4/24/2017Gregory S PatrickCFOSell54,000$32.37$1,747,980.00View SEC Filing  
4/24/2017Padmanabh P BhattVPSell11,806$32.59$384,757.54View SEC Filing  
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.00View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Supernus Pharmaceuticals (NASDAQ SUPN)

Source:
DateHeadline
Supernus Pharmaceuticals, Inc. (SUPN) Earns Buy Rating from B. RileySupernus Pharmaceuticals, Inc. (SUPN) Earns Buy Rating from B. Riley
www.americanbankingnews.com - November 20 at 6:46 PM
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan - PR Newswire (press release)Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan - PR Newswire (press release)
www.prnewswire.com - November 16 at 9:01 AM
Equities Analysts Offer Predictions for Supernus Pharmaceuticals, Inc.s Q4 2017 Earnings (SUPN)Equities Analysts Offer Predictions for Supernus Pharmaceuticals, Inc.'s Q4 2017 Earnings (SUPN)
www.americanbankingnews.com - November 13 at 4:50 AM
Lightning Round: Jim Cramer Is A Seller Of Pandora, Lost Faith In ChipotleLightning Round: Jim Cramer Is A Seller Of Pandora, Lost Faith In Chipotle
www.msn.com - November 11 at 2:12 PM
Zacks: Analysts Anticipate Supernus Pharmaceuticals, Inc. (SUPN) Will Announce Quarterly Sales of $86.59 MillionZacks: Analysts Anticipate Supernus Pharmaceuticals, Inc. (SUPN) Will Announce Quarterly Sales of $86.59 Million
www.americanbankingnews.com - November 11 at 8:10 AM
Stock Traders Buy Large Volume of Call Options on Supernus Pharmaceuticals (SUPN)Stock Traders Buy Large Volume of Call Options on Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - November 11 at 1:50 AM
Jefferies Group Analysts Lower Earnings Estimates for Supernus Pharmaceuticals, Inc. (SUPN)Jefferies Group Analysts Lower Earnings Estimates for Supernus Pharmaceuticals, Inc. (SUPN)
www.americanbankingnews.com - November 10 at 5:10 PM
FY2017 Earnings Estimate for Supernus Pharmaceuticals, Inc. (SUPN) Issued By Cantor FitzgeraldFY2017 Earnings Estimate for Supernus Pharmaceuticals, Inc. (SUPN) Issued By Cantor Fitzgerald
www.americanbankingnews.com - November 10 at 1:37 PM
FY2017 EPS Estimates for Supernus Pharmaceuticals, Inc. Boosted by Analyst (SUPN)FY2017 EPS Estimates for Supernus Pharmaceuticals, Inc. Boosted by Analyst (SUPN)
www.americanbankingnews.com - November 10 at 1:36 PM
Supernus to Present at Three November Healthcare Conferences - GlobeNewswire (press release)Supernus to Present at Three November Healthcare Conferences - GlobeNewswire (press release)
globenewswire.com - November 10 at 10:46 AM
Lightning Round: Jim Cramer Is A Seller Of Pandora, Lost Faith In Chipotle - BenzingaLightning Round: Jim Cramer Is A Seller Of Pandora, Lost Faith In Chipotle - Benzinga
www.benzinga.com - November 10 at 10:46 AM
Supernus Pharmaceuticals, Inc. (SUPN) Downgraded by Zacks Investment ResearchSupernus Pharmaceuticals, Inc. (SUPN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 10 at 6:59 AM
Supernus to Present at Three November Healthcare Conferences - NasdaqSupernus to Present at Three November Healthcare Conferences - Nasdaq
www.nasdaq.com - November 9 at 7:23 PM
RSI Alert: Supernus Pharmaceuticals (SUPN) Now Oversold - NasdaqRSI Alert: Supernus Pharmaceuticals (SUPN) Now Oversold - Nasdaq
www.nasdaq.com - November 9 at 7:23 PM
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day - Motley FoolWhy Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day - Motley Fool
www.fool.com - November 9 at 7:23 PM
Supernus to Present at Three November Healthcare ConferencesSupernus to Present at Three November Healthcare Conferences
finance.yahoo.com - November 9 at 2:12 PM
Edited Transcript of SUPN earnings conference call or presentation 7-Nov-17 2:00pm GMTEdited Transcript of SUPN earnings conference call or presentation 7-Nov-17 2:00pm GMT
finance.yahoo.com - November 9 at 2:12 PM
Equities Analysts Issue Forecasts for Supernus Pharmaceuticals, Inc.s Q4 2017 Earnings (SUPN)Equities Analysts Issue Forecasts for Supernus Pharmaceuticals, Inc.'s Q4 2017 Earnings (SUPN)
www.americanbankingnews.com - November 9 at 9:40 AM
Supernus Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of $1.08 Per Share (SUPN)Supernus Pharmaceuticals, Inc. Expected to Post FY2017 Earnings of $1.08 Per Share (SUPN)
www.americanbankingnews.com - November 9 at 6:44 AM
Supernus Pharmaceuticals, Inc. to Post Q3 2017 Earnings of $0.28 Per Share, B. Riley Forecasts (SUPN)Supernus Pharmaceuticals, Inc. to Post Q3 2017 Earnings of $0.28 Per Share, B. Riley Forecasts (SUPN)
www.americanbankingnews.com - November 8 at 10:15 AM
Supernus Pharmaceuticals, Inc. (SUPN) Raised to Strong-Buy at Zacks Investment ResearchSupernus Pharmaceuticals, Inc. (SUPN) Raised to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - November 8 at 9:51 AM
Supernus Pharmaceuticals, Inc. (SUPN) Upgraded to "Buy" at Stifel NicolausSupernus Pharmaceuticals, Inc. (SUPN) Upgraded to "Buy" at Stifel Nicolaus
www.americanbankingnews.com - November 7 at 11:50 PM
Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super DayWhy Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day
www.fool.com - November 7 at 4:22 PM
Supernus Announces Third Quarter 2017 Financial Results - GlobeNewswire (press release)Supernus Announces Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 7 at 11:33 AM
Supernus Pharmaceuticals, Inc. to Host Earnings CallSupernus Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 7 at 11:33 AM
Supernus Pharmaceuticals, Inc. (SUPN) Announces Quarterly  Earnings ResultsSupernus Pharmaceuticals, Inc. (SUPN) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 9:06 AM
SunTrust Banks Equities Analysts Boost Earnings Estimates for Supernus Pharmaceuticals, Inc. (SUPN)SunTrust Banks Equities Analysts Boost Earnings Estimates for Supernus Pharmaceuticals, Inc. (SUPN)
www.americanbankingnews.com - November 6 at 1:20 AM
Supernus Pharmaceuticals, Inc. (SUPN) Receives Consensus Rating of "Buy" from AnalystsSupernus Pharmaceuticals, Inc. (SUPN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 5 at 1:42 PM
SunTrust Banks, Inc. Reaffirms "Buy" Rating for Supernus Pharmaceuticals, Inc. (SUPN)SunTrust Banks, Inc. Reaffirms "Buy" Rating for Supernus Pharmaceuticals, Inc. (SUPN)
www.americanbankingnews.com - November 4 at 8:22 AM
ETFs with exposure to Supernus Pharmaceuticals, Inc. : October 30, 2017ETFs with exposure to Supernus Pharmaceuticals, Inc. : October 30, 2017
finance.yahoo.com - October 31 at 10:12 AM
Supernus Pharmaceuticals, Inc. (SUPN) Forecasted to Post FY2021 Earnings of $4.00 Per ShareSupernus Pharmaceuticals, Inc. (SUPN) Forecasted to Post FY2021 Earnings of $4.00 Per Share
www.americanbankingnews.com - October 25 at 7:36 PM
Supernus to Host Third Quarter 2017 Earnings Conference CallSupernus to Host Third Quarter 2017 Earnings Conference Call
finance.yahoo.com - October 25 at 2:33 PM
Cowen and Company Analysts Give Supernus Pharmaceuticals, Inc. (SUPN) a $50.00 Price TargetCowen and Company Analysts Give Supernus Pharmaceuticals, Inc. (SUPN) a $50.00 Price Target
www.americanbankingnews.com - October 24 at 6:08 PM
FBR & Co Comments on Supernus Pharmaceuticals, Inc.s FY2019 Earnings (SUPN)FBR & Co Comments on Supernus Pharmaceuticals, Inc.'s FY2019 Earnings (SUPN)
www.americanbankingnews.com - October 24 at 3:26 PM
Supernus Pharmaceuticals, Inc. (SUPN) Receives New Coverage from Analysts at FBR & CoSupernus Pharmaceuticals, Inc. (SUPN) Receives New Coverage from Analysts at FBR & Co
www.americanbankingnews.com - October 22 at 10:26 PM
$77.74 Million in Sales Expected for Supernus Pharmaceuticals, Inc. (SUPN) This Quarter$77.74 Million in Sales Expected for Supernus Pharmaceuticals, Inc. (SUPN) This Quarter
www.americanbankingnews.com - October 22 at 5:04 AM
Comparing Supernus Pharmaceuticals (SUPN) and Eagle Pharmaceuticals (EGRX)Comparing Supernus Pharmaceuticals (SUPN) and Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - October 21 at 2:24 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Supernus ...SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Supernus ...
www.businesswire.com - October 20 at 9:52 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Supernus Pharmaceuticals, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Supernus Pharmaceuticals, Inc.
finance.yahoo.com - October 20 at 9:52 PM
Research Analysts Issue Forecasts for Supernus Pharmaceuticals, Inc.s Q3 2017 Earnings (SUPN)Research Analysts Issue Forecasts for Supernus Pharmaceuticals, Inc.'s Q3 2017 Earnings (SUPN)
www.americanbankingnews.com - October 20 at 8:02 AM
ETFs with exposure to Supernus Pharmaceuticals, Inc. : October 17, 2017ETFs with exposure to Supernus Pharmaceuticals, Inc. : October 17, 2017
finance.yahoo.com - October 18 at 9:05 AM
Critical Review: Supernus Pharmaceuticals (SUPN) vs. The CompetitionCritical Review: Supernus Pharmaceuticals (SUPN) vs. The Competition
www.americanbankingnews.com - October 13 at 8:26 AM
This Company’s Sales Have Grown 1,700% in Just Three YearsThis Company’s Sales Have Grown 1,700% in Just Three Years
www.baystreet.ca - October 12 at 3:45 PM
Critical Survey: Supernus Pharmaceuticals (SUPN) versus Novan (NOVN)Critical Survey: Supernus Pharmaceuticals (SUPN) versus Novan (NOVN)
www.americanbankingnews.com - October 12 at 2:34 PM
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Allergan - PR Newswire (press release)Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Allergan - PR Newswire (press release)
www.prnewswire.com - October 10 at 7:15 AM
Medical Drug Stocks: What Are The Best Wealth Builders Now?Medical Drug Stocks: What Are The Best Wealth Builders Now?
seekingalpha.com - October 7 at 8:52 AM
ETFs with exposure to Supernus Pharmaceuticals, Inc. : October 6, 2017ETFs with exposure to Supernus Pharmaceuticals, Inc. : October 6, 2017
finance.yahoo.com - October 7 at 8:52 AM
Supernus Pharmaceuticals (SUPN) & Its Competitors Head-To-Head AnalysisSupernus Pharmaceuticals (SUPN) & Its Competitors Head-To-Head Analysis
www.americanbankingnews.com - October 7 at 2:08 AM
Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017
finance.yahoo.com - October 3 at 1:09 PM
ETFs with exposure to Supernus Pharmaceuticals, Inc. : September 26, 2017ETFs with exposure to Supernus Pharmaceuticals, Inc. : September 26, 2017
finance.yahoo.com - October 3 at 1:09 PM

Social Media

Financials

Chart

Supernus Pharmaceuticals (NASDAQ SUPN) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.